

HR 7506

New Era of Preventing End-Stage Kidney Disease Act

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 14, 2022

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Apr 15, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/7506>

Sponsor

Name: Rep. Butterfield, G. K. [D-NC-1]

Party: Democratic • **State:** NC • **Chamber:** House

Cosponsors (13 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Bilirakis, Gus M. [R-FL-12]	R · FL		Apr 14, 2022
Rep. Bishop, Sanford D., Jr. [D-GA-2]	D · GA		Jun 7, 2022
Rep. Levin, Mike [D-CA-49]	D · CA		Jul 1, 2022
Rep. Ross, Deborah K. [D-NC-2]	D · NC		Jul 21, 2022
Rep. Wild, Susan [D-PA-7]	D · PA		Jul 21, 2022
Rep. Lofgren, Zoe [D-CA-19]	D · CA		Aug 5, 2022
Rep. Phillips, Dean [D-MN-3]	D · MN		Aug 12, 2022
Rep. Posey, Bill [R-FL-8]	R · FL		Sep 22, 2022
Rep. Burgess, Michael C. [R-TX-26]	R · TX		Oct 28, 2022
Rep. Schrader, Kurt [D-OR-5]	D · OR		Oct 28, 2022
Rep. Peters, Scott H. [D-CA-52]	D · CA		Nov 10, 2022
Rep. Crenshaw, Dan [R-TX-2]	R · TX		Dec 15, 2022
Rep. Davis, Danny K. [D-IL-7]	D · IL		Dec 15, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Apr 15, 2022
Ways and Means Committee	House	Referred To	Apr 14, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Apr 14, 2022)

New Era of Preventing End-Stage Kidney Disease Act

This bill addresses rare kidney diseases through research, training for health professionals, and other means. It also modifies requirements for Medicare drug plan formularies that include drugs for rare diseases or conditions.

The Department of Health and Human Services (HHS) must

- convene a conference focused on diagnosis and treatment of rare kidney diseases;
- study risk factors, access to care (including to genetic and genomic testing), and other matters related to rare kidney diseases; and
- establish grants for supporting kidney disease education and referrals in communities of color.

HHS may award grants to educate and train health professionals about kidney disease and nephrology. Additionally, health professional schools that receive certain HHS funding for educating underrepresented minority individuals must support postgraduate nephrology training.

The National Institutes of Health (NIH) must report on diversity in its kidney disease research. The NIH may also (1) support research on rare kidney diseases that, among other requirements, includes persons of color in study populations; and (2) establish regional centers of excellence for rare kidney diseases.

The Centers for Medicare & Medicaid Services must evaluate methods for (1) treating rare kidney diseases, with a focus on delaying dialysis and transplant; and (2) raising awareness about rare kidney diseases, including in communities of color.

Furthermore, if a Medicare drug plan formulary includes a drug to treat a rare disease or condition, at least two members of the committee that develops or reviews the formulary must have expertise in the field of medicine related to that drug.

Actions Timeline

- **Apr 15, 2022:** Referred to the Subcommittee on Health.
- **Apr 14, 2022:** Introduced in House
- **Apr 14, 2022:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.